MRUS News

The past week saw four IPOs produce insignificant returns. All four deals finished the week at or above the offer price, but none gained more than 5%. The first bank IPO of 2016, Argentina-based Grupo Supervielle dual listed in New York and Buenos Aires; its $281 million IPO raised more than the other three small health care deals combined.  ...read more

Merus, which is developing bispecific antibody treatments for solid tumors, raised $55 million by offering 5.5 million shares at $10. It originally planned to offer 4.3 million shares at a range of $14 to $16. Its new market cap of $158 million is a 29% discount to the one proposed when the company set terms. Merus plans to list on the Nasdaq under the symbol MRUS. Citi and...read more

There are four companies set to debut in the week ahead, but only one company with substantial revenue and profit - small-cap Argentinian bank Grupo Supervielle (SUPV). Three additional deals launched and are set to price in May including the second-largest food distributor US Foods (USFD), set to raise $1 billion. If all deals on the calendar...read more

Merus, which is developing bispecific antibody treatments for solid tumors, announced terms for its IPO on Monday. The Utrecht, Netherlands-based company plans to raise $65 million by offering 4.3 million shares at a price range of $14 to $16. Insiders intend to purchase $33 million worth of shares in the offering. At the midpoint of the proposed range, Merus would command a...read more